Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04713085
Other study ID # 18_20B2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2019
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Friedrich-Alexander-Universität Erlangen-Nürnberg
Contact Sonja Diez, M.D.
Phone 0049 09131 85 32923
Email sonja.diez@uk-erlangen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of neuromodulation for treatment of chronic constipation and fecal incontinence in pediatric patients and to evaluate the differences between the invasive vs. non-invasive approach.


Description:

Patients are selected according to the eligibility requirements. After obtaining informed consent off-label use and potential risks of sacral neuromodulation, all included patients and next of kin give written informed consent to the study. At baseline, patients are randomized to one of the two predefined subgroups: either invasive sacral neuromodulation or non-invasive sacral neuromodulation. Clinical symptoms and outcome variables are compared regarding the beginning of non-invasive sacral neuromodulation or the implantation of the tined lead electrode. Patients are closely monitored within 6 months. Treatment success is evaluated in routine clinical check-ups (week 4/8/12 and 24) and via specialized questionnaires and bowel movement diaries. Quality of life is evaluated at baseline and after 12 and 24 weeks of treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: - age between 2-17 years - informed consent - chronic constipation according to the ROME IV criteria for more than 3 months with or without encopresis/soiling despite underlying diseases such as slow-transit constipation, rectal evacuation disorders or Hirschsprung's disease. - refractory to conventional treatment in an appropriate weight-adapted application (training for bowel movements, lifestyle changes, pelvic floor training, pharmacological options) - in cases of Hirschsprung's disease: diagnosis confirmed histologically by rectal biopsies and in case of resection of an aganglionic segement: period between surgery and SNM at least 1 year - in cases of anorectal malformation or mechanical obstruction: post-surgical status: period between surgery and SNM at least 1 year Exclusion Criteria: - metabolic, inflammatory, and hormonal causes for chronic constipation - toxic megacolon or further emergencies, which must be treated surgically - sacral fractures or substantial differences in the sacral anatomy - inflammatory bowel disorders - rectal prolapse - neuronal malignancies under medical and radiation therapy - seizures

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Invasive Sacral Neuromodulation
Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
Non-invasive Sacral Neuromodulation
External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).

Locations

Country Name City State
Germany Friedrich-Alexander-Universität Erlangen-Nürnberg, Pediatric Surgery Erlangen Bavaria

Sponsors (1)

Lead Sponsor Collaborator
Friedrich-Alexander-Universität Erlangen-Nürnberg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of episodes of abdominal pain Abdominal pain is recorded in number of episodes per week. Its intensity is evaluated via the numeric rating scale (0=no pain, 10=worst imaginable pain). Definition of success: reduction by at least 50% of episodes per week Baseline and 12 and 24 weeks after start of therapy
Primary Change of episodes of fecal incontinence Number of episodes of fecal incontinence per week. Definition of success: reduction by at least 50% of episodes per week Baseline and 12 and 24 weeks after start of therapy
Primary Change of defecation frequency Defecation frequency is measured by number of bowel movements per week. Definition of success: doubling of episodes per week to at least 3 or more bowel movements per week Baseline and 12 and 24 weeks after start of therapy
Primary Change of defecation consistency Defecation consistency is measured daily by the Bristol Stool Scale, which classifies stool consistency from 1 (hard consistency) to 7 (fluid consistency). Definition of success: change of at least 2 points within the scale of 1-7 Baseline and 12 and 24 weeks after start of therapy
Secondary Change of proprioception Improvement of proprioception is measured as mentioned in the specialized questionnaires. Baseline and 12 and 24 weeks after start of therapy
Secondary Episodes of urinary incontinence The number of episodes per week is evaluated with the criterion for a clinically relevant improvement in cases of reduction by at least 50% of episodes per week. Baseline and 12 and 24 weeks after start of therapy
Secondary Change of Quality of Life The quality of life is classified via the 'Revised Children's Quality of Life Questionnaire' (KINDLR). It consists of 24 5-point Likert-scale items, covering 6 quality of life dimensions: physical well-being, emotional well-being, self-esteem, family, friends and daily functioning (school or nursery school/kindergarten). Items are partially reverse scored and linearly transformed to a 0 to 100 scale according to the manual. Higher scores indicate a better quality of life. Baseline and 12 and 24 weeks after start of therapy
Secondary Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) Adverse events are measured as mentioned in the specialized questionnaires: these include cutaneous reactions, urinary incontinence, dysfunction of stimulation or further unknown factors. Baseline and 12 and 24 weeks after start of therapy
See also
  Status Clinical Trial Phase
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Completed NCT05621629 - Management of FI After Surgery of ARM
Recruiting NCT05293353 - Neokare Safety and Tolerability Assessment in Neonates With GI Problems
Recruiting NCT04904081 - Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery Phase 3
Not yet recruiting NCT05749406 - Parental Attitudes to Neoanus Dilatations Post-reconstruction in Anorectal Malformations
Recruiting NCT05450991 - Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung's Disease and Anorectal Malformations
Recruiting NCT06234020 - Frequency of Vertebrospinal Anomalies in Patients Presenting With Anorectal Malformations
Completed NCT04901819 - Longterm Outcomes of Individuals With Anorectal Malformations
Completed NCT04710433 - Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation N/A
Completed NCT05045560 - Study of Antenatal and Postnatal Data of Anorectal Malformations Diagnosed at Montpellier University Hospital Over a 10-year Period (2010-2020)
Enrolling by invitation NCT04106947 - Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations